Mention Cannabis. Watch Your Stock Surge
(Bloomberg) -- New Age Beverages Corp. shares have tripled this month. Alkaline Water Co.’s stock more than doubled. And IntelGenx Technologies Corp. did that in a single day last week.
On the surface, the companies may not have much in common -- one makes trendy Kombucha drinks, another pH-balanced water, while the last makes oral films for medications. But their plans in the emerging legal cannabis market has caught investors’ attention.
New Age Beverages owes its recent rally to a conference presentation earlier this month where company executives showed a slide titled “Tested CBD Beverage in CO,” referring to drinks infused with marijuana-derived cannabidiol. The stock added $14.5 million to its market capitalization that day alone, ending the session at $94.4 million.
The maker of Coco Libre coconut water and Bucha Live Kombucha has since announced plans to debut its portfolio of CBD-infused beverages at a trade show for convenience stores in Las Vegas next month. As of Tuesday, Torrance, California-based New Age carries a valuation of about $190 million.
And it’s not alone. Here are some of the other companies looking to get in on the green rush. A custom index of the cannabis-related stocks shows them outperforming the ETFMG Alternative Harvest exchange-traded fund, as well as the S&P 500, since the start of the year.
The over-the-counter packaging company gained 22 percent Monday on an agreement to package cannabis-infused gummy edibles. The Jacksonville, Florida-based company said the candies "will be the first of several edibles to be packaged by Advantis."
Investors in this high-alkaline bottled-water manufacturer have seen their fortunes grow by 72 percent since the company announced that new products coming to market soon will include a hemp-derived CBD-infused Alkaline88 water.
Even mega-cap Coca-Cola can’t ignore this hot industry. The Atlanta-based soft-drink maker said it’s monitoring the cannabis industry and is interested in CBD-infused drinks. The move follows alcohol maker Constellation Brands’ multi-billion dollar investment in Canopy Growth.
The biotech stock saw a 54 percent spike on September 20 after saying it licenses about 600 compounds that target the same system in the human body that marijuana affects -- even though its products are derived from synthetics and not the cannabis plant itself.
The maker of VersaFilm -- a medication delivery product that dissolves in a patient’s mouth -- has a non-binding letter of intent with pot provider Tilray to develop cannabis-based uses. The stock more than doubled on the announcement.
The e-commerce platform is becoming the website provider of choice for Canada’s pot rollout after signing deals with several provinces and companies, including Aurora Cannabis, to host sales channels.
©2018 Bloomberg L.P.